FDA approves first bioresorbable scaffold with autologous cells for cartilage repair

Vericel Corp (NSDQ:VCEL) shares soared 56% today after the Cambridge, Mass.-based company said the FDA approved its bioresorbable scaffold for cartilage repair. The product, Maci, is the 1st FDA-approved implant to use healthy cartilage tissue from a patient’s own knee to grow cells on the scaffold.

“Different cartilage defects require different treatments, so therapy must be tailored to the patient,” deputy director of the FDA’s Center for Biologics Evaluation & Research Dr. Celia Witten said in prepared remarks. “The introduction of Maci provides surgeons with an additional option for treatment.”

Get the full story at our sister site, Drug Delivery Business News.

The post FDA approves first bioresorbable scaffold with autologous cells for cartilage repair appeared first on MassDevice.

from MassDevice http://ift.tt/2hwQfHQ